PTGX
Protagonist Therapeutics, Inc.
Price Chart
Latest Quote
$83.05
Current Price| Previous Close | $81.80 |
| Open | $81.80 |
| Day High | $84.55 |
| Day Low | $81.14 |
| Volume | 1,258,497 |
Stock Information
| Shares Outstanding | 62.52M |
| Total Debt | $10.75M |
| Cash Equivalents | $576.12M |
| Revenue | $209.22M |
| Net Income | $45.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.19B |
| P/E Ratio | 125.83 |
| EPS (TTM) | $0.66 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 31/42| Debt to Equity | 0.02 |
| Debt to Earnings | 0.04 |
| Current Ratio | 12.48 |
| Quick Ratio | 12.39 |
| Avg Revenue Growth | 372.00% |
| Profit Margin | 63.34% |
| Return on Equity | 40.75% |
| Avg FCF Growth | -66.94% |
| FCF Yield | 3.52% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $83.05 | 1,259,308 |
| 2026-01-30 | $81.80 | 1,174,000 |
| 2026-01-29 | $79.73 | 952,700 |
| 2026-01-28 | $81.76 | 777,200 |
| 2026-01-27 | $83.08 | 507,800 |
| 2026-01-26 | $82.30 | 529,200 |
| 2026-01-23 | $83.10 | 569,300 |
| 2026-01-22 | $84.79 | 609,100 |
| 2026-01-21 | $83.89 | 1,086,100 |
| 2026-01-20 | $83.42 | 901,300 |
| 2026-01-16 | $81.99 | 664,700 |
| 2026-01-15 | $84.75 | 839,300 |
| 2026-01-14 | $85.23 | 1,052,600 |
| 2026-01-13 | $81.36 | 799,000 |
| 2026-01-12 | $80.25 | 739,800 |
| 2026-01-09 | $80.22 | 983,300 |
| 2026-01-08 | $80.20 | 1,487,700 |
| 2026-01-07 | $82.34 | 1,220,400 |
| 2026-01-06 | $82.27 | 731,000 |
| 2026-01-05 | $84.18 | 1,028,100 |
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
đ° Latest News
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Motley Fool âĸ 2026-02-01T05:45:17Z
High Growth Tech Stocks In The US For January 2026
Simply Wall St. âĸ 2026-01-09T11:38:17Z
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge?
Simply Wall St. âĸ 2026-01-08T02:10:55Z
Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis
Investor's Business Daily âĸ 2026-01-06T21:29:12Z
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Pharmaceutical Technology âĸ 2026-01-06T12:05:31Z
Three Stocks That May Be Undervalued In December 2025
Simply Wall St. âĸ 2025-12-15T11:38:04Z
High Growth Tech Stocks In The US Market With Potential
Simply Wall St. âĸ 2025-12-11T11:38:18Z
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory
Insider Monkey âĸ 2025-12-05T21:21:05Z
November 2025's Top Value Picks For Potential Market Opportunities
Simply Wall St. âĸ 2025-11-14T17:38:19Z
High Growth Tech Stocks To Watch In The US This November 2025
Simply Wall St. âĸ 2025-11-12T11:38:10Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $434,433,000 | $60,000,000 | $26,581,000 | $27,357,000 |
| Operating Revenue | $434,433,000 | $60,000,000 | $26,581,000 | $27,357,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $181,590,000 | $153,652,000 | $157,954,000 | $153,202,000 |
| Other Income Expense | $250,000 | $-201,000 | $-80,000 | $-149,000 |
| Other Non Operating Income Expenses | $250,000 | $-201,000 | $-80,000 | $-149,000 |
| Net Non Operating Interest Income Expense | $26,315,000 | $14,898,000 | $4,060,000 | $443,000 |
| Operating Expense | $181,590,000 | $153,652,000 | $157,954,000 | $153,202,000 |
| General And Administrative Expense | $43,462,000 | $33,491,000 | $31,739,000 | $27,196,000 |
| Interest Expense | - | - | $0 | $0 |
| Interest Expense Non Operating | - | - | $0 | $0 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Net Interest Income | $26,315,000 | $14,898,000 | $4,060,000 | $443,000 |
| Interest Income | $26,315,000 | $14,898,000 | $4,060,000 | $443,000 |
| Normalized Income | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Net Income From Continuing And Discontinued Operation | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Total Operating Income As Reported | $252,843,000 | $-93,652,000 | $-131,373,000 | $-125,845,000 |
| Net Income Common Stockholders | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Net Income | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Net Income Including Noncontrolling Interests | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Net Income Continuous Operations | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Pretax Income | $279,408,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Interest Income Non Operating | $26,315,000 | $14,898,000 | $4,060,000 | $443,000 |
| Operating Income | $252,843,000 | $-93,652,000 | $-131,373,000 | $-125,845,000 |
| Special Income Charges | - | - | $0 | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $4.23 | $-1.39 | $-2.60 | $-2.71 |
| Basic EPS | $4.47 | $-1.39 | $-2.60 | $-2.71 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $255,738,000 | $-90,340,000 | $-128,004,000 | $-123,070,000 |
| Reconciled Depreciation | $2,895,000 | $3,312,000 | $3,369,000 | $2,775,000 |
| EBITDA (Bullshit earnings) | $255,738,000 | $-90,340,000 | $-128,004,000 | $-123,070,000 |
| EBIT | $252,843,000 | $-93,652,000 | $-131,373,000 | $-125,845,000 |
| Diluted Average Shares | $65,077,722 | $56,763,559 | $49,042,232 | $46,322,910 |
| Basic Average Shares | $61,566,989 | $56,763,559 | $49,042,232 | $46,322,910 |
| Diluted NI Availto Com Stockholders | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Tax Provision | $4,220,000 | $0 | $0 | $0 |
| Research And Development | $138,128,000 | $120,161,000 | $126,215,000 | $126,006,000 |
| Selling General And Administration | $43,462,000 | $33,491,000 | $31,739,000 | $27,196,000 |
| Other Gand A | $43,462,000 | $33,491,000 | $31,739,000 | $27,196,000 |
| Total Unusual Items | - | - | $0 | $0 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $675,295,000 | $336,677,000 | $215,608,000 | $300,021,000 |
| Total Assets | $744,725,000 | $357,951,000 | $247,928,000 | $347,695,000 |
| Total Non Current Assets | $153,084,000 | $2,374,000 | $4,851,000 | $6,959,000 |
| Other Non Current Assets | $225,000 | $225,000 | $225,000 | $225,000 |
| Current Assets | $591,641,000 | $355,577,000 | $243,077,000 | $340,736,000 |
| Prepaid Assets | $4,238,000 | $3,628,000 | $5,670,000 | $8,503,000 |
| Receivables | $168,490,000 | $10,332,000 | $52,000 | $5,333,000 |
| Other Receivables | $248,000 | $76,000 | $42,000 | $975,000 |
| Accrued Interest Receivable | $3,242,000 | $256,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $418,913,000 | $341,617,000 | $237,355,000 | $326,900,000 |
| Cash And Cash Equivalents | $97,249,000 | $186,727,000 | $125,744,000 | $123,665,000 |
| Other Current Assets | - | - | $42,000 | $975,000 |
| Taxes Receivable | - | - | $0 | $2,792,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Restricted Cash | - | - | - | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $10,866,000 | $1,141,000 | $3,656,000 | $5,858,000 |
| Long Term Debt And Capital Lease Obligation | $10,356,000 | $0 | $1,141,000 | $3,658,000 |
| Current Debt And Capital Lease Obligation | $510,000 | $1,141,000 | $2,515,000 | $2,200,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $69,430,000 | $21,274,000 | $32,320,000 | $47,674,000 |
| Total Non Current Liabilities Net Minority Interest | $22,032,000 | $0 | $1,141,000 | $3,658,000 |
| Non Current Deferred Liabilities | $11,676,000 | $0 | - | - |
| Current Liabilities | $47,398,000 | $21,274,000 | $31,179,000 | $44,016,000 |
| Current Deferred Liabilities | $18,891,000 | $3,000 | $69,000 | $2,500,000 |
| Payables And Accrued Expenses | $16,919,000 | $13,344,000 | $23,628,000 | $32,191,000 |
| Payables | $4,378,000 | $871,000 | $4,055,000 | $2,007,000 |
| Other Payable | $74,000 | $99,000 | $415,000 | $407,000 |
| Total Tax Payable | $2,689,000 | $0 | - | - |
| Income Tax Payable | $2,689,000 | $0 | - | - |
| Accounts Payable | $1,615,000 | $772,000 | $3,640,000 | $1,600,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $675,295,000 | $336,677,000 | $215,608,000 | $300,021,000 |
| Total Equity Gross Minority Interest | $675,295,000 | $336,677,000 | $215,608,000 | $300,021,000 |
| Stockholders Equity | $675,295,000 | $336,677,000 | $215,608,000 | $300,021,000 |
| Gains Losses Not Affecting Retained Earnings | $-82,000 | $-105,000 | $-359,000 | $-299,000 |
| Other Equity Adjustments | $-82,000 | $-105,000 | $-359,000 | $-299,000 |
| Retained Earnings | $-340,522,000 | $-615,710,000 | $-536,755,000 | $-409,362,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $61,035,139 | $57,708,613 | $49,339,252 | $47,838,330 |
| Share Issued | $61,035,139 | $57,708,613 | $49,339,252 | $47,838,330 |
| Tangible Book Value | $675,295,000 | $336,677,000 | $215,608,000 | $300,021,000 |
| Invested Capital | $675,295,000 | $336,677,000 | $215,608,000 | $300,021,000 |
| Working Capital | $544,243,000 | $334,303,000 | $211,898,000 | $296,720,000 |
| Capital Lease Obligations | $10,866,000 | $1,141,000 | $3,656,000 | $5,858,000 |
| Total Capitalization | $675,295,000 | $336,677,000 | $215,608,000 | $300,021,000 |
| Additional Paid In Capital | $1,015,898,000 | $952,491,000 | $752,722,000 | $709,682,000 |
| Capital Stock | $1,000 | $1,000 | $0 | $0 |
| Common Stock | $1,000 | $1,000 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $10,356,000 | $0 | $1,141,000 | $3,658,000 |
| Current Deferred Revenue | $18,891,000 | $3,000 | $69,000 | $2,500,000 |
| Current Capital Lease Obligation | $510,000 | $1,141,000 | $2,515,000 | $2,200,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,078,000 | $6,786,000 | $4,967,000 | $7,125,000 |
| Current Accrued Expenses | $12,541,000 | $12,473,000 | $19,573,000 | $30,184,000 |
| Investments And Advances | $140,252,000 | $0 | - | $0 |
| Net PPE | $12,607,000 | $2,149,000 | $4,626,000 | $6,734,000 |
| Accumulated Depreciation | $-7,035,000 | $-6,234,000 | $-5,254,000 | $-4,258,000 |
| Gross PPE | $19,642,000 | $8,383,000 | $9,880,000 | $10,992,000 |
| Leases | $2,424,000 | $963,000 | $913,000 | $877,000 |
| Other Properties | $15,771,000 | $6,277,000 | $7,878,000 | $9,092,000 |
| Machinery Furniture Equipment | $1,447,000 | $1,143,000 | $1,089,000 | $1,023,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $165,000,000 | $10,000,000 | $10,000 | $1,566,000 |
| Other Short Term Investments | $321,664,000 | $154,890,000 | $111,611,000 | $203,235,000 |
| Dueto Related Parties Current | - | - | $69,000 | $899,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $182,797,000 | $-70,845,000 | $-108,932,000 | $-108,966,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $184,152,000 | $-70,236,000 | $-108,137,000 | $-107,865,000 |
| Cash Flow From Continuing Operating Activities | $184,152,000 | $-70,236,000 | $-108,137,000 | $-107,865,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-1,355,000 | $-609,000 | $-795,000 | $-1,101,000 |
| Investing Cash Flow | $-299,483,000 | $-39,258,000 | $91,468,000 | $-15,860,000 |
| Cash Flow From Continuing Investing Activities | $-299,483,000 | $-39,258,000 | $91,468,000 | $-15,860,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $0 | $132,100,000 | $14,553,000 | $123,829,000 |
| Financing Cash Flow | $25,853,000 | $170,477,000 | $18,838,000 | $129,923,000 |
| Cash Flow From Continuing Financing Activities | $25,853,000 | $170,477,000 | $18,838,000 | $129,923,000 |
| Net Other Financing Charges | $-600,000 | $-769,000 | $-163,000 | $-189,000 |
| Net Common Stock Issuance | $0 | $132,100,000 | $14,553,000 | $123,829,000 |
| Common Stock Issuance | $0 | $132,100,000 | $14,553,000 | $123,829,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $1,530,000 | $0 | $0 | $0 |
| End Cash Position | $97,474,000 | $186,952,000 | $125,969,000 | $123,890,000 |
| Beginning Cash Position | $186,952,000 | $125,969,000 | $123,890,000 | $117,818,000 |
| Effect Of Exchange Rate Changes | $0 | $0 | $-90,000 | $-126,000 |
| Changes In Cash | $-89,478,000 | $60,983,000 | $2,169,000 | $6,198,000 |
| Proceeds From Stock Option Exercised | $26,453,000 | $39,146,000 | $4,448,000 | $6,283,000 |
| Net Investment Purchase And Sale | $-298,128,000 | $-38,649,000 | $92,263,000 | $-14,759,000 |
| Sale Of Investment | $323,574,000 | $152,396,000 | $307,137,000 | $271,830,000 |
| Purchase Of Investment | $-621,702,000 | $-191,045,000 | $-214,874,000 | $-286,589,000 |
| Net PPE Purchase And Sale | $-1,355,000 | $-609,000 | $-795,000 | $-1,101,000 |
| Purchase Of PPE | $-1,355,000 | $-609,000 | $-795,000 | $-1,101,000 |
| Change In Working Capital | $-122,610,000 | $-19,511,000 | $-7,766,000 | $-3,314,000 |
| Change In Other Working Capital | $30,567,000 | - | $-1,601,000 | $-12,876,000 |
| Change In Other Current Liabilities | $-2,226,000 | $-2,743,000 | $-2,661,000 | $-2,170,000 |
| Change In Payables And Accrued Expense | $7,817,000 | $-8,531,000 | $-11,500,000 | $15,874,000 |
| Change In Accrued Expense | $4,289,000 | $-5,597,000 | $-12,715,000 | $19,097,000 |
| Change In Payable | $3,528,000 | $-2,934,000 | $1,215,000 | $-3,223,000 |
| Change In Account Payable | $842,000 | $-2,868,000 | $2,045,000 | $-1,390,000 |
| Change In Tax Payable | $2,689,000 | $0 | $0 | - |
| Change In Income Tax Payable | $2,689,000 | $0 | $0 | - |
| Change In Prepaid Assets | $-3,768,000 | $1,753,000 | $3,754,000 | $-3,227,000 |
| Change In Receivables | $-155,000,000 | $-9,990,000 | $4,242,000 | $-915,000 |
| Stock Based Compensation | $37,554,000 | $29,293,000 | $24,202,000 | $16,395,000 |
| Amortization Of Securities | $-8,875,000 | $-4,569,000 | $-549,000 | $1,830,000 |
| Depreciation Amortization Depletion | $2,895,000 | $3,312,000 | $3,369,000 | $2,775,000 |
| Depreciation And Amortization | $2,895,000 | $3,312,000 | $3,369,000 | $2,775,000 |
| Depreciation | $2,895,000 | $3,312,000 | $3,369,000 | $2,775,000 |
| Net Income From Continuing Operations | $275,188,000 | $-78,955,000 | $-127,393,000 | $-125,551,000 |
| Other Non Cash Items | - | $194,000 | - | - |
| Repayment Of Debt | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Deferred Tax | - | - | $0 | $0 |
| Deferred Income Tax | - | - | $0 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |